Premier Biomedical, Inc. (BIEI), has released the results of a completed phase-1 mouse testing of its breast cancer therapy. Premier Biomedical's cancer treatment methodology outperformed chemotherapy, the standard treatment option demonstrating a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded nineteen days after first treatment.
Twenty-five days into the study, the mice given Premier Biomedical's treatment experienced a 100 percent survival rate without encountering a single cancer-related fatality. In contrast, nearly a third of the mice subjected to chemotherapy were deceased, while the control group fared far worse than either of the other groups.
Most significantly, the tumors within the mice given Premier Biomedical's treatment shrunk in size in the days following the application. In contrast, the size of the tumors within the mice subjected to chemotherapy continued to grow rapidly throughout the duration of the study.
The mice which received the Premier Biomedical's treatment gained weight over the course of the study and consistently had a greater weight than both the untreated mice and the mice which were subjected to chemotherapy. In animal cancer studies, greater weight is typically a strong indication of greater health.
Mitchell S. Felder, M.D. inventor of the core technology said "Every doctor has seen a patient whose mortality was undoubtedly certain, yet miraculously fought against all odds and lived. In these mice test results, an unlikely biological process appears to occur in which the immune system is enabled by the treatment and fights off and kills the cancer. It is this process that we believe we are replicating in Premier Biomedical's anti-cancer methodologies."
In response to the laboratory studies, William A. Hartman, CEO and President of Premier Biomedical, Inc. stated, "It is an understatement to say that the results produced here are remarkable. Premier Biomedical's methodology is undoubtedly in its infancy. But with the right funding, support from our organizational partners and from the compassionate cancer community, we have good reason to believe that we can cure breast cancer. Just as significantly, we have good reason to believe that we may be able to finally offer a more effective treatment option that saves patients from the harm of chemotherapy, which remains the best current and available treatment today."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the Over The Counter Bulletin Board under the ticker symbol "BIEI."www.premierbiomedicalinc.com
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
William A. Hartman, CEO